Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.

Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K

The Journal of clinical endocrinology and metabolism1 Feb 1998Cited by 53 (Europe PMC)

PMID9467572DOI10.1210/jcem.83.2.4602PepBankPUB-09467572

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. 4 results from people.

01HumanCase report or seriesEfficacy outcome
In a patient with leprechaunism, intermittent and continuous rhIGF-I sustained serum total IGF-I within the normal range.
In plain wordsIn a patient with leprechaunism, injected and infused rhIGF-I maintained normal total blood IGF-I levels.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableSerum total IGF-I maintenance
Study
n = 1
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous injection and infusionAs given in this study (human).
Source sentences
Summary
This sustained the serum total IGF-I level, but not the serum IGFBP-3 level, within the normal range.
2 context sentences(design, population, supporting numbers)
Summary · context
To increase the serum total IGF-I level, we administered rhIGF-I with combination therapy of intermittent and continuous s.c. injection.
Summary · context
In the same patient, we also investigated the pharmacokinetics of IGF-I and the long-term effect of rhIGF-I treatment on metabolic control and physical growth.
Report a problemFND-0946757205
02HumanCase report or seriesEfficacy outcome
In a patient with leprechaunism, rhIGF-I did not sustain serum IGFBP-3 within the normal range.
In plain wordsIn a patient with leprechaunism, rhIGF-I did not maintain normal blood IGFBP-3 levels.
Peptide
IGF-1 (mecasermin)
Outcome
Direction not reportedSerum IGFBP-3 maintenance
Study
n = 1
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · subcutaneous injection and infusionAs given in this study (human).
Source sentences
Summary
This sustained the serum total IGF-I level, but not the serum IGFBP-3 level, within the normal range.
2 context sentences(design, population, supporting numbers)
Summary · context
To increase the serum total IGF-I level, we administered rhIGF-I with combination therapy of intermittent and continuous s.c. injection.
Summary · context
In the same patient, we also investigated the pharmacokinetics of IGF-I and the long-term effect of rhIGF-I treatment on metabolic control and physical growth.
Report a problemFND-0946757206
03HumanCase report or seriesEfficacy outcome
In a patient with leprechaunism, rhIGF-I maintained growth rate nearly within the normal range.
In plain wordsIn a patient with leprechaunism, rhIGF-I maintained a nearly normal growth rate.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableGrowth rate
Study
n = 1
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1.6 mg/kg daily · subcutaneous injection and infusion · 6 yr and 10 monthsAs given in this study (human).
Source sentences
Summary
Administration of rhIGF-I at total daily dose of 1.6 mg/kg maintained her growth rate and hemoglobin A1c level nearly within the normal range.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient was treated with combination therapy of rhIGF-I by both s.c. injection and continuous s.c. infusion for 6 yr and 10 months.
Summary · context
In the same patient, we also investigated the pharmacokinetics of IGF-I and the long-term effect of rhIGF-I treatment on metabolic control and physical growth.
Report a problemFND-0946757207
04HumanCase report or seriesEfficacy outcome
In a patient with leprechaunism, rhIGF-I maintained hemoglobin A1c nearly within the normal range.
In plain wordsIn a patient with leprechaunism, rhIGF-I maintained nearly normal long-term blood sugar.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableHemoglobin A1c
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.6 mg/kg daily · subcutaneous injection and infusion · 6 yr and 10 monthsAs given in this study (human).
Source sentences
Summary
Administration of rhIGF-I at total daily dose of 1.6 mg/kg maintained her growth rate and hemoglobin A1c level nearly within the normal range.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient was treated with combination therapy of rhIGF-I by both s.c. injection and continuous s.c. infusion for 6 yr and 10 months.
Summary · context
In the same patient, we also investigated the pharmacokinetics of IGF-I and the long-term effect of rhIGF-I treatment on metabolic control and physical growth.
Report a problemFND-0946757208
05LabIn vitro (cells)Activity measurement
In leprechaunism patient fibroblasts, IGF-I binding was normal.
In plain wordsIn lab tests, leprechaunism-derived fibroblasts showed normal IGF-I binding.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableIGF-I binding
Study
humann: not reported in source
Fibroblasts from a patient with leprechaunism
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
The patient's fibroblasts showed normal binding of IGF-I, normal phosphorylation of the beta-subunit of the IGF-I receptor, and normal [3H]thymidine incorporation in response to IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the biological actions of recombinant human insulin-like growth factor I (rhIGF-I) in fibroblasts derived from a patient with leprechaunism.
Report a problemFND-0946757201
06LabIn vitro (cells)Mechanism
In leprechaunism patient fibroblasts, IGF-I receptor beta-subunit phosphorylation was normal.
In plain wordsIn lab tests, leprechaunism-derived fibroblasts showed normal IGF-I receptor phosphorylation.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableIGF-I receptor beta-subunit phosphorylation
Study
humann: not reported in source
Fibroblasts from a patient with leprechaunism
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
The patient's fibroblasts showed normal binding of IGF-I, normal phosphorylation of the beta-subunit of the IGF-I receptor, and normal [3H]thymidine incorporation in response to IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the biological actions of recombinant human insulin-like growth factor I (rhIGF-I) in fibroblasts derived from a patient with leprechaunism.
Report a problemFND-0946757202
07LabIn vitro (cells)Activity measurement
In leprechaunism patient fibroblasts, thymidine incorporation in response to IGF-I was normal.
In plain wordsIn lab tests, leprechaunism-derived fibroblasts showed a normal thymidine response to IGF-I.
Peptide
IGF-1 (mecasermin)
Outcome
Not applicableThymidine incorporation
Study
humann: not reported in source
Fibroblasts from a patient with leprechaunism
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
The patient's fibroblasts showed normal binding of IGF-I, normal phosphorylation of the beta-subunit of the IGF-I receptor, and normal [3H]thymidine incorporation in response to IGF-I.
1 context sentence(design, population, supporting numbers)
Summary · context
In the present study, we investigated the biological actions of recombinant human insulin-like growth factor I (rhIGF-I) in fibroblasts derived from a patient with leprechaunism.
Report a problemFND-0946757203

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

08HumanEndogenous levelCase report or seriesOther
In a patient with leprechaunism, recombinant GH induced a minimal serum total IGF-I response.
In plain wordsIn a patient with leprechaunism, growth hormone produced a minimal response in natural IGF-I levels.
Peptide
IGF-1 (mecasermin)
Outcome
Direction not reportedSerum total IGF-I response to GH
Study
n = 1
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Administration of recombinant human GH at the dose of 2.0 IU/kg for 3 consecutive days induced a minimal response of serum total IGF-I and IGF-binding protein-3 (IGFBP-3), suggesting partial GH resistance.
1 context sentence(design, population, supporting numbers)
Summary · context
In the same patient, we also investigated the pharmacokinetics of IGF-I and the long-term effect of rhIGF-I treatment on metabolic control and physical growth.
This result measures the body's own IGF-1 (mecasermin). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0946757204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.